A comparison of whether catheter ablation improves the prognosis (all-cause mortality and/or the composite endpoint of MACE) and reduces the recurrence rate of atrial fibrillation (AF) in patients with AF and heart failure with preserved ejection fraction (HFpEF), compared to anti-atrial arrhythmia drugs (AAD). This trial was randomly divided into two groups: the anti-AAD drug group and the catheter ablation group.
Age ≥18 years.
The patient is willing and able to comply with the protocol and has provided written informed consent.
Paroxysmal or persistent atrial fibrillation (AF).（Persistent AF was defined as AF which is sustained beyond 7 days, or lasting less than seven days but necessitating pharmacologic or electric cardioversion. Included within the category of persistent AF is 'long-standing persistent AF', defined as continuous AF of >1-year duration. AF episodes had to be documented in the last 3 months prior to enrollment by ECG, Holter ECG, Loop Recorder, memory of the implanted device (ICD/CRT-D), or any other suitable device.）
Failure or intolerance of antiarrhythmic drug therapy or unwillingness to take antiarrhythmic drugs.
Previous left heart ablation procedure for AF.
Contraindication to chronic anticoagulation therapy or heparin.
Documented left atrial diameter >6 cm, optimally from the parasternal long-axis view.
Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 2 months prior to enrollment.
Shanghai Chest Hospital
Lead sponsor
The Third Affiliated Hospital of Anhui Medical University
Collaborator
Hefei Second People's Hospital
Collaborator
The Second People's Hospital of Anhui Province
Collaborator
Hefei Binhu Hospital
Collaborator